# A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

> **NCT01214720** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 607 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** bevacizumab [Avastin]

## Key facts

- **NCT ID:** NCT01214720
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 607 (ACTUAL)
- **Last updated:** 2014-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01214720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01214720, "A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01214720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*